4O VHIO immune gene expression profiling (VIGex) panel, a tool to explore tumor immune microenvironment

2020 ◽  
Vol 31 ◽  
pp. S2-S3
Author(s):  
F.M. Mancuso ◽  
Z. Ogbah ◽  
R. Fasani ◽  
D. Lo Giacco ◽  
L. Ramos ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profiling ◽  
Expression Profiling ◽  
Immune Gene ◽  
Immune Microenvironment ◽  
Immune Gene Expression ◽  
Tumor Immune Microenvironment

scholarly journals 581P VHIO immune gene expression profiling (VIGex) panel, a tool to explore tumour immune microenvironment

2020 ◽  
Vol 31 ◽  
pp. S492-S493
Author(s):  
F.M. Mancuso ◽  
Z. Ogbah ◽  
R. Fasani ◽  
D.G. Lo Giacco ◽  
L. Ramos ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profiling ◽  
Expression Profiling ◽  
Immune Gene ◽  
Immune Microenvironment ◽  
Immune Gene Expression

Different patterns of non immediate allergic reaction to BRAF inhibitor in two patients with metastatic melanoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21052-e21052 ◽  
Author(s):  
Miguel-Angel Berciano-Guerrero ◽  
Rocío Lavado ◽  
Álvaro Montesa ◽  
Martina Alvarez ◽  
Angela Santonja ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lymph Node ◽  
Gene Expression Profiling ◽  
Metastatic Melanoma ◽  
Expression Profiling ◽  
Braf Inhibitor ◽  
Braf V600e ◽  
Immune Gene ◽  
Skin Reactions ◽  
Immune Gene Expression

e21052 Background: Non immediate allergic reactions (niAR) related with oncology drugs are a rare entity. Usually, it is called Drug Reaction with eosinophilia and sistemic symptoms (“DRESS”), occurring at first ten days of treatment.Recently, the treatment of metastatic melanoma (MM) has included new drugs in patients wtih BRAF V600E mutation. Despite skin reactions are usual, niAR to these drugs have not been reported. We present 2 clinical cases with mm treated with BRAFi, developing such niAR. Methods: Patient 1: 47yo female with lymph node relapse and multiple subcutaneous skin metastases (previously pT1N0M0 melanoma) that received nivolumab in adjuvant setting. BRAF-mutated. She starts with Vemurafenib-Cobimetinib (V-C). At 8 days, niAR (maculo-papular exantema G4, fever G2). After discontinuation of this treatment (3 weeks), it is changed to Dabrafenib(50%)-Trametinib (D-T). With only 1 dose, skin niAR (G3) is newly developed. Biopsy are taken at the beginning (T0), during (T1) and after desentizitation (T2). Patient 2: 60 yo female, lung and lymph node relapse of melanoma (previously pT2bN0M0) after IFN-alpha adjuvant 2 years before. BRAF-mutated. Start with V-C. At 9 days, skin niAR (G4), with fever (G1). Discontinuation of treatment. Biopsys and blood test are taken (T0, T1 and T2). Gene expression was performed with PanCancer Immune Profiling Panel Nanostring™ in this points. Results: Different lymphocytic subpopulations in blood and biopsy at acute phase are showed in table 1. Immune gene expression profiling found decreased expression of 5 genes: UBC, IL8, IL32, NFKB1A and FOS, increasing IFNGR1 (pt 1). In both of pts, desensitizitation protocol by Allergologists was made succesfully, with incremental oncology drugs and steroid reduction protocol. Both of pts had a maior partial response (RECIST), even the scarce of the drug received. Conclusions: D and V develop important “of class” skin niAR. Different immunologic patterns are related with this niAR. Previous exposition to IFN or anti-PD1 therapy might modulate such response. Immune gene expression profiling could be used as a method to identify biomarkers. Desensitization with BRAFi has enough efficacy and tolerance.

scholarly journals Immune gene expression profiling reveals heterogeneity in luminal breast tumors

2019 ◽  
Author(s):  
Bin Zhu ◽  
Shelly Lap Ah Tse ◽  
Difei Wang ◽  
Hela Koka ◽  
Tongwu Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Gene Expression Profiling ◽  
T Cell Activation ◽  
Expression Profiling ◽  
Expression Patterns ◽  
Luminal Breast Cancer ◽  
Immune Gene ◽  
Disease Heterogeneity ◽  
Immune Gene Expression

AbstractDisease heterogeneity of immune gene expression patterns of luminal breast cancer (BC) has not been well studied. We performed immune gene expression profiling of tumor and adjacent normal tissue in 92 Asian luminal BC patients and identified three distinct immune subtypes. Tumors in one subtype exhibited signs of T-cell activation, lower ESR1/ESR2 expression ratio and higher expression of immune checkpoint genes, nonsynonymous mutation burden, APOBEC-signature mutations, and increasing body mass index compared to other luminal tumors. Tumors in a second subtype were characterized by increased expression of interferon-stimulated genes and enrichment for TP53 somatic mutations. The presence of three immune subtypes within luminal BC was replicated in cases drawn from The Cancer Genome Atlas and a Korean breast cancer study. Our findings suggest that immune gene expression and associated genomic features could be useful to further stratify luminal BC beyond the current luminal A/B classification.

Sign in / Sign up

Export Citation Format

Share Document